View in EDS HTML Full Text PDF Full Text

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Authors: Ren Z; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China., Huang Y; Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China., Guo Y; Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China., Hou MM; Division of Hematology and Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan., Wang W; Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, China., Kuang M; The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Hao C; Beijing Cancer Hospital, Beijing, China., Wang W; West China Hospital Sichuan University, Chengdu, Sichuan, China., Zhang Y; Gastroenterology Department, Harbin Medical University Cancer Hospital, Harbin, China., Song T; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Dai C; Shengjing Hospital of China Medical University, Shenyang, China., Kuo HT; Chi Mei Medical Center, Tainan, Taiwan.; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan., Bao Z; Solid Tumors, BeOne Medicines, Ltd, Shanghai, China., Zuo Y; Clinical Development, BeOne Medicines, Ltd, Shanghai, China., Wang L; Statistics, BeOne Medicines, Ltd, Beijing, China., Zhu F; Clinical Biomarkers, BeOne Medicines, Ltd, Shanghai, China., Fan J; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. fan.jia@zs-hospital.sh.cn.; Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. fan.jia@zs-hospital.sh.cn.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Apr 28; Vol. 75 (5). Date of Electronic Publication: 2026 Apr 28.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42047833
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ren+Z%22">Ren Z</searchLink>; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Huang+Y%22">Huang Y</searchLink>; Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Guo+Y%22">Guo Y</searchLink>; Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Hou+MM%22">Hou MM</searchLink>; Division of Hematology and Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+W%22">Wang W</searchLink>; Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Kuang+M%22">Kuang M</searchLink>; The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Hao+C%22">Hao C</searchLink>; Beijing Cancer Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Wang+W%22">Wang W</searchLink>; West China Hospital Sichuan University, Chengdu, Sichuan, China.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Gastroenterology Department, Harbin Medical University Cancer Hospital, Harbin, China.<br /><searchLink fieldCode="AU" term="%22Song+T%22">Song T</searchLink>; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Dai+C%22">Dai C</searchLink>; Shengjing Hospital of China Medical University, Shenyang, China.<br /><searchLink fieldCode="AU" term="%22Kuo+HT%22">Kuo HT</searchLink>; Chi Mei Medical Center, Tainan, Taiwan.; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Bao+Z%22">Bao Z</searchLink>; Solid Tumors, BeOne Medicines, Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zuo+Y%22">Zuo Y</searchLink>; Clinical Development, BeOne Medicines, Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Statistics, BeOne Medicines, Ltd, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Zhu+F%22">Zhu F</searchLink>; Clinical Biomarkers, BeOne Medicines, Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Fan+J%22">Fan J</searchLink>; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. fan.jia@zs-hospital.sh.cn.; Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. fan.jia@zs-hospital.sh.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2026 Apr 28; Vol. 75 (5). <i>Date of Electronic Publication: </i>2026 Apr 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42047833
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-026-04399-8
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ren Z
      – PersonEntity:
          Name:
            NameFull: Huang Y
      – PersonEntity:
          Name:
            NameFull: Guo Y
      – PersonEntity:
          Name:
            NameFull: Hou MM
      – PersonEntity:
          Name:
            NameFull: Wang W
      – PersonEntity:
          Name:
            NameFull: Kuang M
      – PersonEntity:
          Name:
            NameFull: Hao C
      – PersonEntity:
          Name:
            NameFull: Wang W
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Song T
      – PersonEntity:
          Name:
            NameFull: Dai C
      – PersonEntity:
          Name:
            NameFull: Kuo HT
      – PersonEntity:
          Name:
            NameFull: Bao Z
      – PersonEntity:
          Name:
            NameFull: Zuo Y
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Zhu F
      – PersonEntity:
          Name:
            NameFull: Fan J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 04
              Text: 2026 Apr 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 75
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1